Adults recovering from surgery now have access to a pain drug that works through an entirely different biological mechanism than opioids. The FDA approved JOURNAVX, the brand name for suzetrigine, as 50 mg oral tablets for moderate-to-severe acute pain in adults. It is the first non-opioid analgesic to reach the market from a new drug class in decades, arriving as hospitals and insurers search for alternatives to medications that carry addiction risk.
Why suzetrigine’s arrival pressures acute-care prescribing
Opioids have dominated acute pain treatment for decades, and that dominance has come at a well-documented cost. Millions of Americans have developed dependence after short courses of postoperative painkillers, and health systems have spent years tightening prescribing guidelines without having a mechanistically distinct alternative to offer. Suzetrigine changes that equation. It is a selective NaV1.8 inhibitor, meaning it blocks a specific sodium channel involved in pain signaling rather than binding to the mu-opioid receptors that produce both relief and the euphoria tied to addiction.
The practical question for hospital formulary committees is straightforward: if suzetrigine performs well enough to replace opioids as a first-line option after common surgeries, the total volume of opioid milligram equivalents dispensed in postoperative settings should drop in a measurable way. Linked prescription and insurance claims datasets already track opioid dispensing at the procedure level, so a real decline would show up within roughly 12 months of broad formulary adoption. That signal has not yet appeared because the drug is new, but the data infrastructure to detect it already exists.
Regulators have underscored the potential shift. In announcing its decision, the FDA described JOURNAVX as a novel, first-in-class non-opioid treatment for moderate-to-severe acute pain, emphasizing that it targets a different pathway than traditional narcotics. The agency’s approval notice highlights that the drug is intended for short-term use in adults when other non-opioid options are inadequate or not expected to provide sufficient relief.
For hospital leaders, that framing matters. Many systems have already implemented multimodal pain protocols that combine acetaminophen, NSAIDs, local anesthetics, and, when necessary, opioids. Suzetrigine offers a way to build a regimen in which opioids move further down the ladder, potentially reserved for rescue therapy rather than routine first-line prescribing.
Phase 3 trial results in abdominoplasty and bunionectomy
The approval rests on a clinical evidence package that includes both Phase 2 and Phase 3 trials. Early randomized studies evaluated VX-548, suzetrigine’s investigational designation, in postoperative pain models after abdominoplasty and bunionectomy. Those Phase 2 results, published in The New England Journal of Medicine, established that NaV1.8 inhibition could produce statistically significant pain relief compared with placebo and supported dose selection for larger trials.
Two subsequent Phase 3 randomized, double-blind trials tested suzetrigine against both placebo and an active comparator in the same surgical populations. Those Phase 3 data, reported in JAMA, confirmed the drug’s efficacy on primary pain-intensity endpoints and evaluated its performance on key secondary measures alongside hydrocodone-acetaminophen. Across the studies, suzetrigine reduced pain scores more than placebo and showed clinically meaningful relief over the acute postoperative period covered by the protocols.
The FDA characterized JOURNAVX as a first-in-class non-opioid analgesic in its review, a designation that reflects both the novelty of the NaV1.8 target and the absence of any approved competitor in the same drug class. For surgeons and anesthesiologists, that means the drug cannot be slotted into an existing therapeutic category; instead, it represents a distinct mechanism that can be layered onto or substituted within current multimodal strategies.
Registry information from the pivotal trials, including identifiers such as NCT05558410 for abdominoplasty and NCT05661734 for a broader acute-pain population, provides additional detail on enrolled demographics, safety signals, and outcome measures. The FDA’s Drug Trials Snapshots for JOURNAVX break down who participated by sex, race, age, and ethnicity, offering a public record of how representative the study populations were and where evidence gaps may remain for subgroups commonly seen in community practice.
What the evidence shows-and what it does not
The clinical record supporting suzetrigine is strongest for short-duration acute pain after abdominoplasty and bunionectomy, procedures that generate predictable, moderate-to-severe postoperative discomfort. Within that window, the trials suggest that NaV1.8 inhibition can provide meaningful analgesia without the respiratory depression, constipation, and euphoria associated with opioids.
However, the limits of the evidence are equally important for clinicians deciding where the drug fits in practice. No long-term safety or efficacy data beyond the acute treatment window used in the Phase 3 protocols have been posted to public trial registries or included in FDA review documents. That leaves open questions about the drug’s profile over weeks or months of intermittent use, or in patients who experience recurring acute pain episodes from repeated procedures or injuries.
Head-to-head trials against other non-opioid analgesics, such as NSAIDs or acetaminophen, in diverse outpatient populations have not been published. The existing comparisons pit suzetrigine against placebo and against hydrocodone-acetaminophen, which tells clinicians how it stacks up against the drug they most want to replace but not how it compares with safer alternatives already in wide use. For many lower-intensity procedures, those older agents may remain the default until comparative effectiveness data emerge.
Post-marketing adverse event surveillance specific to NaV1.8 inhibition is also in its earliest stages. No dedicated FDA or HHS safety signal reports for this mechanism have appeared yet, which is expected for a newly approved drug but leaves prescribers relying on the trial safety database rather than real-world experience. As JOURNAVX moves into broader clinical use, spontaneous adverse event reports and observational studies will be critical to identifying any rare but serious risks that did not surface in the controlled trial environment.
How adoption could reshape opioid use after surgery
The next development to watch is whether large health systems and pharmacy benefit managers add JOURNAVX to their acute-care formularies and, if so, whether claims data show a corresponding drop in opioid prescriptions after common surgeries. Commercial and Medicare Part D databases already capture procedure codes, inpatient orders, and outpatient dispensing, making it possible to track shifts in opioid milligram equivalents at the level of specific operations such as knee arthroscopy, hernia repair, or cesarean delivery.
If suzetrigine is adopted as a first-line option for appropriate patients, analysts would expect to see a decline in initial opioid fills, smaller quantities dispensed when opioids are used, and fewer refills in the weeks following surgery. Those trends would not prove causation on their own, but they would offer an early signal that a mechanistically novel non-opioid can move the needle where prescribing limits and education campaigns have had only partial success.
Cost and coverage decisions will influence that trajectory. A new branded analgesic will likely be more expensive than generic hydrocodone-acetaminophen or ibuprofen, at least initially. Payers may respond with prior authorization requirements that restrict use to specific procedures or to patients who cannot tolerate NSAIDs or other standard therapies. Hospitals, in turn, will have to decide whether the potential benefits-in reduced opioid exposure, fewer opioid-related adverse events, and possibly shorter lengths of stay-justify the added pharmacy spend.
What patients and clinicians should discuss now
For now, suzetrigine offers a promising but still partially characterized option. Surgeons, anesthesiologists, and primary care clinicians will need to weigh its benefits and uncertainties on a case-by-case basis. Key considerations include the expected intensity and duration of postoperative pain, the patient’s history of substance use disorder or prior opioid exposure, their cardiovascular and renal risk profile (which can limit NSAID use), and their preferences about balancing pain relief with potential side effects.
Patients facing surgery should ask their care teams how JOURNAVX fits into the overall pain management plan, whether it is available at the hospital or ambulatory center where they will be treated, and what is known-and not yet known-about its safety and effectiveness compared with both opioids and older non-opioid drugs. Those conversations will help determine whether this first-in-class NaV1.8 inhibitor becomes a routine part of postoperative care or remains a more targeted option reserved for select clinical scenarios.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
